Sign in
CompletedPhase 2/3

Growth Hormone in Decompensated Liver Cirrhosis

Key facts

Who runs it
Post Graduate Institute of Medical Education and Research, Chandigarh
Where
India1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
Phase
Phase 2/3
People taking part
96 people enrolled
Started
1 Feb 2022
Ended
31 Dec 2024
Type of study
Interventional, 2 groupsOne group gets no study treatment, for comparison.
Treatments tested
  • Growth Hormone
Record updated
16 December 2025

Who can take part

Age
18 years to 80 years
Sex
Women and men
Healthy volunteers
Cannot take part
Show the full registry criteria (14)Hide the full registry criteria

Who can take part

  • Age above 18 years
  • Patients having confirmed diagnosis of decompensated cirrhosis, any etiology
  • Patients having given an informed and written consent for participation in the study

Who cannot take part

  • Diagnosis of concomitant hepatocellular carcinoma or other active malignancy
  • Patients on antiviral therapy for HCV, HBV or corticosteroid for autoimmune hepatitis those who have received it within the last 6 months
  • TIPS insertion within 6 months prior to study inclusion
  • Acute on chronic liver failure
  • Severe cardiac dysfunction NYHA grade III/IV, Chronic obstructive pulmonary disease GOLD C or above
  • Known hypersensitivity to GH
  • Uncontrolled diabetes (Hb A1c ≥ 9) or diabetic retinopathy
  • Active alcohol abuse in last 3 months
  • Human immunodeficiency virus seropositivity
  • Pregnancy \& lactation
  • Active sepsis

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Globally, cirrhosis and liver cancer carries a huge burden and accounts for about 3.5% (2 million) of all deaths every year. Once decompensated, i.e. development of ascites, variceal bleed, encephalopathy, and jaundice, the life expectancy is markedly reduced to a median of two years. The definitive treatment in this stage, i.e., liver transplantation is limited by cost, lack of donors, and life-long immunosuppression.

Read full original descriptionShow less

In addition to complications due to portal hypertension and hepatic insufficiency, decompensated cirrhosis is associated with malnutrition, sarcopenia, immune dysfunction, and impaired regeneration. Patients with cirrhosis are growth hormone (GH) resistant, with reduced insulin-like growth factor, which are linked to malnutrition and poor liver regeneration in cirrhosis. Diverse preclinical and clinical investigations in vitro and in vivo, have shown a benefit of GH in GH deficient, elderly and HIV positive patients. GH therapy in cirrhosis has been shown to improve nitrogen economy and to improve the GH resistance in a small pilot study by Donaghy et al. Also, GH therapy of short duration has shown to increase IGF1 levels, IGFBP-3 levels in patients of cirrhosis. GH therapy has also been shown to improve liver regeneration and protein synthesis after hepatectomy in patients of HCC with cirrhosis. However, there is a scarcity of data on clinical impact of long term administration of GH therapy in patients of cirrhosis. Hence, we undertook the present study to study the effect of growth hormone on clinical outcomes, malnutrition, immune cells and liver regeneration in patients with cirrhosis.

The 2 groups in the trial

  • Standard Medical treatmentNo study treatment, for comparison

    Standard medical therapy: diuretics, lactulose, rifaximin, diuretics, albumin infusion, nutritional support (as required)

  • Growth hormone + Standard medical therapyTreatment being tested

    GH therapy will be initiated at a low dose of 2U/day and titrated slowly based on IGF-1 levels) subcutaneously for 1 year.

    Treatment: Growth Hormone

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Impact of Repurposed Growth Hormone Treatment on Clinical, Nutritional, Immunological and Regenerative Parameters in Decompensated Liver Cirrhosis: a Randomized Control Trial
Record updated
16 December 2025